[Today's IR] Yuhan, SKC, HLB Panagene and others
Predicted impact: Low
Technology research presented at a conference; no revenue or contract impact disclosed.
HLB PanageneHLB파나진
046210 · KOSDAQ · ₩046210 · HLB파나진
₩1,300▲ ₩14 (1.09%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −23.53%
- Market cap
- ₩59B
- Enterprise value
- ₩45B
- P/E
- —
- P/B
- 0.8×
- Dividend yield
- 0.0%
- ROE
- −4.5%
- Net margin
- −22.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−55.8% from the high
₩980Today: ₩1,286 – ₩1,324₩2,940
Returns
- 1W−10.8%
- 1M−9.2%
- 3M+29.0%
- 6M−38.5%
- YTD−25.1%
- 1Y−23.5%
- Volume today
- 121,850
- 0.1× the 20-day average
- Traded today
- ₩158M
- Listed shares
- 45,527,960
- EPS (12 months)
- −₩72
- Earnings yield −5.5%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 25 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Routine IR event listings with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat18% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
HLB Panagene stock overview
HLB Panagene (HLB파나진, KRX: 046210) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean specialty biotech firm developing products based on PNA (Peptide Nucleic Acid), an artificial gene material. Its shares closed at ₩1,300 on Oct 28, 2026, up 1.09% on the day, giving it a market value of ₩59B.
Key facts
- Market cap
- ₩59B
- Sector
- Biotech & Pharma
- Latest price change
- +1.09%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean specialty biotech firm developing products based on PNA (Peptide Nucleic Acid), an artificial gene material.
Quick answers about HLB Panagene
- What does HLB Panagene do?
- The company is a Korean specialty biotech firm developing products based on PNA (Peptide Nucleic Acid), an artificial gene material. Its main businesses are PNA materials, molecular diagnostics (including cancer companion diagnostics and automated nucleic acid extraction equipment), and immunodiagnostics through its subsidiary BioSquare, which uses quantum dot-based rapid test cartridges. It supplies PNA materials to research and diagnostics customers worldwide and is expanding into spatial proteomics analysis services in Korea.
- What is the market cap of HLB Panagene?
- The market capitalisation of HLB Panagene was ₩59B at the close on Oct 28, 2026.
- Who are the largest shareholders of HLB Panagene?
- According to the latest official filings, the largest reported holders are HLB (20.82%, as of Aug 27, 2026); Park Jun-gon (6.38%, as of Aug 13, 2026); Kim Seong-gi (4.98%, as of Aug 26, 2025).
- When is the next earnings report from HLB Panagene?
- Korean companies rarely announce results dates in advance. Based on when HLB Panagene filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean specialty biotech firm developing products based on PNA (Peptide Nucleic Acid), an artificial gene material. Its main businesses are PNA materials, molecular diagnostics (including cancer companion diagnostics and automated nucleic acid extraction equipment), and immunodiagnostics through its subsidiary BioSquare, which uses quantum dot-based rapid test cartridges. It supplies PNA materials to research and diagnostics customers worldwide and is expanding into spatial proteomics analysis services in Korea.
Written by AI from the company's latest annual report.
- Korean name
- HLB파나진
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 장인근
- Founded
- Jul 1976
- Listed
- Aug 2000
- Listed shares
- 45,527,960
- Fiscal year ends
- Month 12
- Website
- www.hlbpanagene.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
HLB Panagene unveils PNA payload optimization technology, a key AOC element, at OTS
Predicted impact: Low· Actual: −5.1% vs sector, volume 0.5× normal (5 trading days)
Technology disclosure at a conference; no size or revenue impact given.
HLB Panagene shares 'PNA payload optimization' research results at OTS 2026
Predicted impact: Low· Actual: −5.1% vs sector, volume 0.5× normal (5 trading days)
Research presentation at a conference; no financial size disclosed.
Recent filings
See all- Investor relations (IR) eventOct 27, 2026
- Investor relations (IR) eventOct 12, 2026
- Insider shareholding reportAug 27, 2026
- 5%+ holding reportAug 27, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: HLB Panagene / HLB파나진 / 046210 / KRX:046210
Source: KRX statistical information